Pharmsynthez (MOEX:LIFE)

Market Cap	1.36B
Revenue (ttm)	344.17M -18.9%
Net Income	-303.66M
EPS	-1.02
Shares Out	301.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,528,600
Average Volume	9,839,310
Open	4.205
Previous Close	4.090
Day's Range	4.200 - 4.900
52-Week Range	2.645 - 7.000
Beta	0.10
RSI	63.97
Earnings Date	May 19, 2026

About Pharmsynthez

Public Joint-Stock Company "Pharmsynthez", a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia, Europe, the United States, and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Glaumax, Vazostenon, Neostim, Fludarabel, Fenazide, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company "Pharmsynthez" was founded in 1996 and is based in Saint Petersb...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Country: Russia
• Stock Exchange: Moscow Stock Exchange
• Ticker Symbol: LIFE

Financial Performance

In 2022, Pharmsynthez's revenue was 379.67 million, a decrease of -13.38% compared to the previous year's 438.33 million. Losses were -207.49 million, -70.25% less than in 2021.